-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The combination of plasma phosphorylated- tau (P-tau) protein and other available biomarkers may provide accurate Alzheimer's disease (AD) dementia risk prediction.
The combination of plasma phosphorylated- tau (P-tau) protein and other available biomarkers may provide accurate Alzheimer's disease (AD) dementia risk prediction.
Sebastian Palmqvist et al .
The registration flow chart of BioFINDER samples.
The registration flow chart of BioFINDER samples.
Model selection process and performance for predicting AD dementia within 4 years.
Model selection process and performance for predicting AD dementia within 4 years.
Comparison with clinically predicted AD dementia within 4 years
Comparison with clinically predicted AD dementia within 4 yearsThe model selection and performance of ADNI predicting AD dementia within 4 years were compared with the model selected in BioFINDER.
The model selection and performance of ADNI predicting AD dementia within 4 years were compared with the model selected in BioFINDER.
Cross validation and algorithm implementation.
Cross validation and algorithm implementation.
The study carried out plasma P-tau , plasma Aβ42/Aβ40 , plasma neurofilament light chain, APOE genotype, simple cognitive test and AD- specific magnetic resonance imaging measurement.
4 years, plasma in plasma P-tau217 P-tau217 in the BioFINDER BioFINDER accurately predicted accurately predicted the AD ( (the AD area under the curve area under the curve (the AUC) = 0.
In summary, the plasma in plasma P of tau- P of tau- binding simple cognitive tests and binding simple cognitive tests and the APOE the APOE genotyping may significantly improve genotyping may significantly improve the AD the AD of the diagnostic prediction of diagnostic prediction , Diagnose and promote the recruitment of AD trials.
Original source
Palmqvist, S.
Palmqvist, S.
, Tideman, P.
, Cullen, N.
et al.
Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Nat Med(2021).
https://doi.
org/10.
1038/ Z-s41591-021-01348 the Palmqvist, S.
, Tideman, P.
, Cullen, N.
et Al.
Nat Med
in this message
